Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Advanced Refractory Solid Tumors Based on Precise Thymalfasin-regulated PRaG Mode: an Open-label, Prospective, Multicenter Study (PRaG 5.0 Study)

NCT05790447 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT05790447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05790447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Advanced Refractory Solid Tumors Based on Precise Thymalfasin-regulated PRaG Mode: an Open-label, Prospective, Multicenter Study (PRaG 5.0 Study)
Lead sponsor
Second Affiliated Hospital of Soochow University
Phase
Phase 2
Overall status
Unknown status
Start date
April 1, 2023
Completion date
December 31, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, refractory tumor